Drugs / Beclabuvir
Beclabuvir
Trials 21 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT00947245 | Oct 2014 → Feb 2015 | hepatitis C virus infection | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 1 | NCT02175602 | Jun → Aug 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02108639 | Apr → Jun 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02104843 | Apr → May 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02112110 | Apr → May 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02103569 | Apr → Jul 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02095860 | Apr → May 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02084953 | Apr → May 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02045966 | Feb → Apr 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00996879 | May → Sep 2013 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00664625 | May 2008 → Jun 2009 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT02309450 | Dec 2014 → Nov 2015 | hepatitis C virus infection | ANRS, Emerging Infectious Diseases | Withdrawn | No outcome recorded |
| Phase 2 | NCT02175966 | Jul 2014 → Jan 2015 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02124044 | Feb 2014 → Mar 2016 | hepatitis C virus infection | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 2 | NCT01455090 | Nov 2011 → Mar 2014 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01193361 | Oct 2010 → Jun 2011 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02170727 | Jun 2014 → Jun 2015 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01979939 | Dec 2013 → Aug 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01973049 | Dec 2013 → Aug 2014 | chronic hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02292966 | Jul 2015 → Jun 2016 | chronic hepatitis C virus infection | Kirby Institute | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02098616 | Jul 2014 → Feb 2016 | chronic hepatitis C virus infection | Timothy Morgan, MD | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02045693 Background | Feb → Apr 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Beclabuvir | “All participants will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.” NCT02292966 ↗1“Asunaprevir (ASV) and Daclatasvir (DCV) and BMS-791325 (Beclabuvir)” NCT02124044 ↗ |
| Known as | BECLABUVIR HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4105584 ↗ |
| Known as | BMS 791325 | “All patients will receive an all-oral HCV tritherapy with Asunaprevir (200mg), Daclatasvir (30mg) and BMS-791325 (75mg) in a fixed-dose combination (FDC) tablet, twice a day (1...” NCT02309450 ↗21“Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325” NCT02095860 ↗ “BMS 791325 75 mg table by mouth twice daily for 24 Weeks” NCT01455090 ↗ |
| Known as | BMS-791325 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4105584 ↗ |
| Known as | BMS-791325-08 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4105584 ↗ |
| Action | Inhibit | “BMS-791325 is a nonnucleoside inhibitor of hepatitis C virus (HCV) NS5B polymerase” PMID 24733462 ↗ Apr 2014 |
| Modality | Small molecule | “BMS-791325 is a nonnucleoside inhibitor of hepatitis C virus (HCV) NS5B polymerase” PMID 24733462 ↗ Apr 2014 |
| Route | Oral | “Capsules, Oral, Once Daily, Single Dose” NCT00664625 ↗ |